Back to results
US 2026/0199462 A1Published application
Anti-il5r antibody formulations
OwnerSaba Ghazvini, Cassandra Mankusinventors
Life of this patent
Estimating the term…
Abstract
Provided herein are anti-IL5R antibody formulations containing an amount of surfactant below critical micelle concentration (CMC) of the surfactant and methods of using such formulations.
Claims46
A pharmaceutical formulation, comprising:
- (i) an antibody or antigen binding fragment thereof comprising a heavy chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:
- 1;
- a heavy chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:2;
- and a heavy chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:3;
- a light chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:4;
- a light chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:5;
- and a light chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:
- 6;
- and
- (ii) a surfactant at an amount below the critical micelle concentration (CMC) of said surfactant, wherein the surfactant is not polysorbate 20 (PS20).
7 more elements
(canceled)
-48. (canceled)
-58. (canceled)
-64. (canceled)
Dependencies are inferred from the claim text.